A Answers (1)
The U.S. Food and Drug Administration (FDA) approved the first generic version of Copaxone in early 2015. The drug, which is known by the generic name glatiramer acetate, is approved to reduce the frequency of relapses in people with the relapsing-remitting type of multiple sclerosis. It is given as a daily injection.
This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.